Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

In the Media

  • September 22, 2021

The Dales Report – InMed Pharmaceuticals Positioned For Growth As Cannabinoid Supply Sales Poised For Imminent “Take Off”

Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, on the fast-growing synthesized cannabinoid industry and the market opportunity of rare cannabinoids.

—
By Benjamin A. Smith On Sep 22, 2021

Although the purveyors of the production of rare cannabinoids don’t generally receive comparable coverage as larger multi-state operators or licensed producers, perhaps they should. According to InMed Pharmaceuticals Inc. (Nasdaq: INM) CEO Eric Adams, the industry is headed for outsized growth, driven by biosynthesizing breakthroughs that are driving down the cost to produce rare cannabinoids. With its definitive agreement to acquire BayMedica Inc. last week, InMed is poised to take a leadership position in this booming industry.

The BayMedica platform incorporates a multi-step process where living organisms use enzymes to catalyze the conversion of simple substrates into complex products, such as cannabinoids. Its biosynthetic production method is designed to deliver natural cannabinoids such as cannabichromene (CBC), cannabidivarin (CBDV) and tetrahydrocannabivarin (THCV) that are identical to those found in hemp and cannabis. In isolation, such cannabinoids have been found to contain a host of wellness benefits that can be injected into various consumer packaged goods (CPG).

Read full article here in The Dales Report.

 

Full Article
Source: The Dales Report

Share this post

Latest Articles

What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should

Read More
August 18, 2023

What makes cannabinoids an interesting pharmaceutical target?

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the role of the endocannabinoid system? How do cannabinoids interact with the

Read More
August 18, 2023

What is the difference between illegal synthetics and bioidentical synthesized cannabinoids?

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What are illegal synthetic cannabinoids? How are illegal synthetic cannabinoids different from bioidentical synthesized

Read More
July 18, 2023
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • INM-900 Series for Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*